These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25857701)

  • 1. Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings.
    Poletti P; Merler S; Ajelli M; Manfredi P; Munywoki PK; Nokes D; Melegaro A
    BMC Med; 2015 Mar; 13():49. PubMed ID: 25857701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income Country Setting.
    Kinyanjui TM; House TA; Kiti MC; Cane PA; Nokes DJ; Medley GF
    PLoS One; 2015; 10(9):e0138018. PubMed ID: 26390032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.
    Nokes DJ; Okiro EA; Ngama M; Ochola R; White LJ; Scott PD; English M; Cane PA; Medley GF
    Clin Infect Dis; 2008 Jan; 46(1):50-7. PubMed ID: 18171213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach.
    Pan-Ngum W; Kinyanjui T; Kiti M; Taylor S; Toussaint JF; Saralamba S; Van Effelterre T; Nokes DJ; White LJ
    Vaccine; 2017 Jan; 35(2):403-409. PubMed ID: 27914740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing respiratory syncytial virus (RSV) hospitalization in a lower-income country by vaccinating mothers-to-be and their households.
    Brand SP; Munywoki P; Walumbe D; Keeling MJ; Nokes DJ
    Elife; 2020 Mar; 9():. PubMed ID: 32216871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination against RSV: is maternal vaccination a good alternative to other approaches?
    Kaaijk P; Luytjes W; Rots NY
    Hum Vaccin Immunother; 2013 Jun; 9(6):1263-7. PubMed ID: 23442726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.
    Campbell PT; Geard N; Hogan AB
    BMC Med; 2020 Nov; 18(1):319. PubMed ID: 33176774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.
    Browne SK; Beeler JA; Roberts JN
    Vaccine; 2020 Jan; 38(2):101-106. PubMed ID: 31706809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and epidemiologic features of respiratory syncytial virus.
    Hall CB; Simőes EA; Anderson LJ
    Curr Top Microbiol Immunol; 2013; 372():39-57. PubMed ID: 24362683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy.
    Scheltema NM; Kavelaars XM; Thorburn K; Hennus MP; van Woensel JB; van der Ent CK; Borghans JAM; Bont LJ; Drylewicz J
    Vaccine; 2018 Jul; 36(31):4693-4700. PubMed ID: 29941327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-based estimates of transmission of respiratory syncytial virus within households.
    Kombe IK; Munywoki PK; Baguelin M; Nokes DJ; Medley GF
    Epidemics; 2019 Jun; 27():1-11. PubMed ID: 30591267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
    Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
    Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: A sample size analysis.
    Riddell CA; Bhat N; Bont LJ; Dupont WD; Feikin DR; Fell DB; Gebretsadik T; Hartert TV; Hutcheon JA; Karron RA; Nair H; Reiner RC; Shi T; Sly PD; Stein RT; Wu P; Zar HJ; Ortiz JR;
    Vaccine; 2018 Dec; 36(52):8100-8109. PubMed ID: 30473186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal RSV vaccine development. Where to from here?
    Gunatilaka A; Giles ML
    Hum Vaccin Immunother; 2021 Nov; 17(11):4542-4548. PubMed ID: 34499565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Atwell JE; Lutz CS; Sparrow EG; Feikin DR
    Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya.
    Munywoki PK; Koech DC; Agoti CN; Lewa C; Cane PA; Medley GF; Nokes DJ
    J Infect Dis; 2014 Jun; 209(11):1685-92. PubMed ID: 24367040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.
    Koltai M; Moyes J; Nyawanda B; Nyiro J; Munywoki PK; Tempia S; Li X; Antillon M; Bilcke J; Flasche S; Beutels P; Nokes DJ; Cohen C; Jit M
    BMC Med; 2023 Mar; 21(1):120. PubMed ID: 37004062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.